Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

Elia Boccellato; Lorenzo Comba; Rita Tavarozzi; Claudia Castellino; Myriam Foglietta; Daniele Mattei; Marco LADETTO; Massimo Massaia; Alessia Castellino

doi:10.3390/cancers17132239

Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

Elia Boccellato
, Lorenzo Comba
, Rita Tavarozzi
, Claudia Castellino
, Myriam Foglietta
, Daniele Mattei
, Marco LADETTO
, Massimo Massaia
, Alessia Castellino

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

: Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...].

Lingua originale	Inglese
Rivista	Cancers
Volume	17
Numero di pubblicazione	13
DOI	https://doi.org/10.3390/cancers17132239
Stato di pubblicazione	Pubblicato - 2025

Keywords

bispecific antibodies
mantle cell lymphoma
monoclonal antibodies
post-CART
relapsed/refractory

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3390/cancers17132239

https://hdl.handle.net/11579/212622

Altri file e collegamenti

handle

Cita questo

@article{bb6e1253de974ea6aee5c7620cbeefe9,

title = "Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells",

abstract = ": Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...].",

keywords = "bispecific antibodies, mantle cell lymphoma, monoclonal antibodies, post-CART, relapsed/refractory, bispecific antibodies, mantle cell lymphoma, monoclonal antibodies, post-CART, relapsed/refractory",

author = "Elia Boccellato and Lorenzo Comba and Rita Tavarozzi and Claudia Castellino and Myriam Foglietta and Daniele Mattei and Marco LADETTO and Massimo Massaia and Alessia Castellino",

note = "Publisher Copyright: {\textcopyright} 2025 by the authors.",

year = "2025",

doi = "10.3390/cancers17132239",

language = "English",

volume = "17",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

AU - Boccellato, Elia

AU - Comba, Lorenzo

AU - Tavarozzi, Rita

AU - Castellino, Claudia

AU - Foglietta, Myriam

AU - Mattei, Daniele

AU - LADETTO, Marco

AU - Massaia, Massimo

AU - Castellino, Alessia

PY - 2025

Y1 - 2025

N2 - : Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...].

AB - : Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...].

KW - bispecific antibodies

KW - mantle cell lymphoma

KW - monoclonal antibodies

KW - post-CART

KW - relapsed/refractory

KW - bispecific antibodies

KW - mantle cell lymphoma

KW - monoclonal antibodies

KW - post-CART

KW - relapsed/refractory

UR - https://iris.uniupo.it/handle/11579/212622

U2 - 10.3390/cancers17132239

DO - 10.3390/cancers17132239

M3 - Article

SN - 2072-6694

VL - 17

JO - Cancers

JF - Cancers

IS - 13

ER -

Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo